Experimental shot takes aim at Hard-to-Treat sarcomas
NCT ID NCT05755113
First seen Feb 28, 2026 · Last updated May 02, 2026 · Updated 5 times
Summary
This study tests an experimental drug, tigilanol tiglate, injected directly into tumors in people with advanced or metastatic soft tissue sarcoma of the arms, legs, or body wall. The goal is to see if the drug can shrink or destroy the treated tumors. About 40 adults will take part, and researchers will also monitor side effects and how much drug enters the bloodstream.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT-TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Centre
RECRUITINGNew York, New York, 10065, United States
Contact
Conditions
Explore the condition pages connected to this study.